Company Profile
Immunocore Holdings plc Stock Price, News & Analysis
- Ticker:
- IMCR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United Kingdom
Stock performance
33.77 USD (-3.51%)
Close
Last updated: July 27, 2026
1.5B USD
Market cap
Why the stock is moving
As of Jul 27, 2026, IMCR closed down 3.51% at $33.77. No new same-company headline was identified in the current news window.
Company overview
Business overview
Immunocore is an immunotherapy company focused on T-cell receptor biology and oncology programs.
Geographic Base and Sector Classification
Headquartered in the United Kingdom and listed on NASDAQ as an ADR, Immunocore has a global biotech footprint.
Business Model Characteristics
Its model combines commercial oncology revenue with platform development and additional immunology programs.
Position Within the Biotechnology Landscape
Immunocore is a differentiated platform biotech whose stock reacts to oncology data, label expansion, and pipeline validation.
Future catalysts
Immunocore's catalysts are tebentafusp expansion beyond uveal melanoma and combination work that can widen the immuno-oncology franchise. The key question is whether the platform can keep turning one approved asset into a broader growth story.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
LEGN · Source: Legend Biotech Corporation
- 03
- 04
- 05
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Immunocore Holdings plc (IMCR)?
Immunocore Holdings plc (IMCR) most recently closed at 33.77 USD, a -3.51% move versus the previous session.
What is the market cap of Immunocore Holdings plc (IMCR)?
Immunocore Holdings plc currently has a market capitalization of 1.5B USD on BioPharmSignal.
What does Immunocore Holdings plc do?
Immunocore is an immunotherapy company focused on T-cell receptor biology and oncology programs.
On which exchange is IMCR stock listed?
Immunocore Holdings plc (IMCR) is associated with NASDAQ, United Kingdom, Biopharma.
What is Immunocore?
Immunocore's catalysts are tebentafusp expansion beyond uveal melanoma and combination work that can widen the immuno-oncology franchise.
Which conditions is Immunocore Holdings plc targeting with Immunocore?
Immunocore Holdings plc is associated with oncology based on its company overview and current catalyst commentary.
How does Immunocore Holdings plc describe recent progress with Immunocore?
Immunocore's catalysts are tebentafusp expansion beyond uveal melanoma and combination work that can widen the immuno-oncology franchise.
What is T-cell?
Immunocore is an immunotherapy company focused on T-cell receptor biology and oncology programs.